Plasma nucleosome levels in node-negative breast cancer patients

被引：42

作者：

Kuroi K. ^{[1
]}

Tanaka C. ^{[1
]}

Toi M. ^{[1
]}

机构：

[1] Department of Surgery, Tokyo Metropolitan Komagome Hospital, Bunkyoku, Tokyo 113-8677

来源：

Breast Cancer | 1999年 / 6卷 / 4期

关键词：

Apoptosis; Breast cancer; Nucleosome; Prognostic factor;

D O I：

10.1007/BF02966454

中图分类号：

学科分类号：

摘要：

Background: A nucleosome is a primary repeating unit of organized DNA in chromatin, and cell death may lead to increased levels of circulating nucleosomes in plasma (PNLs) in various circumstances such as inflammation, pulmonary embolism, autoimmune disease and cancer. Materials and Methods: We investigated PNL s in 96 patients with stage O-III breast cancer (nodenegative, n = 57; node-positive, n = 39), and in 111 women without any evidence of disease as healthy controls. PNLs were detected using the Cell Death Detection ELISA plus kit (Boehringer Mannheim, Japan). Results: The PNLs in normal controls were 0.010±0.012 units (mean±SD), while PNLs were significantly higher in both node-negative breast cancer (0.153+0.242) and node-positive breast cancer patients (0.116+0.172) (p<0.01). When PNLs were classified as high (>0.10) and low (≦0.10), no correlation was found between high PNLs and clinicopathological factors such as tumor size, menopausal status, estrogen receptor status, histological type and lymphatic or venous spread in node-negative breast cancer. The relapse-free survival of patients with high PNLs tended to be better than those with low PNLs in both node-negative and node-positive breast cancer. Conclusion: Increased PNLs were found in breast cancer patients, and PNLs seem promising as a new prognostic factor for both node-negative and node-positive breast cancer.

引用

页码：361 / 364

页数：3

共 19 条

[1]

Fournie G.J., Circulating DNA and lupus nephritis, Kidney International, 33, 2, pp. 487-497, (1988)

[2]

Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J., Free DNA in the serum of cancer patients and the effect of therapy, Cancer Research, 37, 3, pp. 646-650, (1977)

[3]

Shapiro B., Chakrabarty M., Cohn E.M., Leon S.A., Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease, Cancer, 51, 11, pp. 2116-2120, (1983)

[4]

Stroun M., Anker P., Lyautey J., Isolation and characterization of DNA from the plasma of cancer patients, European Journal of Cancer and Clinical Oncology, 23, 6, pp. 707-712, (1987)

[5]

Giacona M.B., Ruben G.C., Iczkowski K.A., Roos T.B., Porter D.M., Sorenson G.D., Cell-free DNA in human blood plasma: Length measurements in patients with pancreatic cancer and healthy controls, Pancreas, 17, 1, pp. 89-97, (1998)

[6]

Vasioukhin V., Anker P., Maurice P., Lyautey J., Lederrey C., Stroun M., Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia, British Journal of Haematology, 86, 4, pp. 774-779, (1994)

[7]

Chen Y.Q., Stroun M., Magnenat J.L., Et al., Microsatellite alterations in plasma DNA of small cell lung cancer patients, Nat Med, 9, pp. 1033-1034, (1996)

[8]

Nawroz H., Koch W., Anker P., Stroun M., Sidransky D., Microsatellite alterations in serum DNA of head and neck cancer patients, Nature Medicine, 2, 9, pp. 1035-1037, (1996)

[9]

Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, pp. 1-56, (1996)

[10]

Le Lann A.D., Fournie G.J., Boissier L., Toutain P.-L., Benoist H., In vitro inhibition of natural-killer-mediated lysis by chromatin fragments, Cancer Immunology Immunotherapy, 39, 3, pp. 185-192, (1994)

← 1 2 →